Chemistry: molecular biology and microbiology – Animal cell – per se ; composition thereof; process of... – Method of regulating cell metabolism or physiology
Reexamination Certificate
2011-08-09
2011-08-09
Leavitt, Maria (Department: 1633)
Chemistry: molecular biology and microbiology
Animal cell, per se ; composition thereof; process of...
Method of regulating cell metabolism or physiology
C435S325000, C435S372000
Reexamination Certificate
active
07993919
ABSTRACT:
A method is disclosed herein for inducing differentiation of a B cell progenitor into a memory B cells and/or a plasma cell. The method includes contacting a population of cells including a mature B cell or a B cell progenitor with an effective amount of IL-21, and isolating memory B cells or plasma cells. In one embodiment, the B cell progenitor is an immature B cell. A method is also disclosed for enhancing an immune response. The method includes contacting a population of cells including a B cell progenitor with an effective amount of IL-21, and isolating memory B cells or plasma cells. The memory B cells arid/or the plasma cell are then introduced into the subject to enhance the immune response. A method is also disclosed for treating a subject with a condition comprising a specific deficiency of at least one of memory B cells and plasma cells. A method is disclosed for identifying an agent with a physiological effect on one or more of a memory B cell and a plasma cell differentiation. A method is also disclosed for identifying agents that inhibit an activity of IL-21.
REFERENCES:
patent: 6307024 (2001-10-01), Novak et al.
patent: 2002/0128446 (2002-09-01), Novak et al.
patent: 2002/0137677 (2002-09-01), Sprecher et al.
patent: 2003/0003545 (2003-01-01), Ebner et al.
patent: 2003/0108549 (2003-06-01), Carter et al.
patent: 2003/0125524 (2003-07-01), Novak et al.
patent: 2003/0134390 (2003-07-01), Presnell et al.
patent: 2003/0138433 (2003-07-01), Newell et al.
patent: 2005/0193434 (2005-09-01), Leonard et al.
patent: 2006/0057123 (2006-03-01), Ettinger et al.
patent: WO 99/61617 (1999-12-01), None
patent: WO 01/77171 (2001-10-01), None
patent: WO 03/028630 (2003-04-01), None
patent: WO 03/040313 (2003-05-01), None
patent: WO 03/052083 (2003-06-01), None
patent: WO 03/082212 (2003-10-01), None
patent: WO 2004/003156 (2004-01-01), None
patent: WO 2005/052139 (2005-06-01), None
Voet, Biochemistry John Wiley and Sons, 1990, pp. 126-128.
Guo et al., Protein tolerance to random amino acid change.Proc Natl Acad Sci U S A. Jun. 22, 2004;101(25):9205-10. Epub Jun. 14, 2004.
Riddell et al., T-cell mediated rejection of gene-modified HIV-specific cytotoxic T lymphocytes in HIV-infected patients.Nat Med. Feb. 1996;2(2):216-23.
Vogelsang GB, Hess AD.Graft-versus-host disease: new directions for a persistent problem. Blood. Oct. 1, 1994;84(7):2061-7.
Gilboa Immunotherapy of cancer with genetically modified tumor vaccines. Semin Oncol. Feb. 1996;23(1):101-7.
Moroz et al., J Immunol. Jul. 15, 2004;173(2):900-9; IL-21 enhances and sustains CD8+ T cell responses to achieve durable tumor immunity: comparative evaluation of IL-2, IL-15, and IL-21.
Kimchi-Sarfaty Cet al., A “silent” polymorphism in the MDR1 gene changes substrate specificity.Science. Jan. 26, 2007;315(5811):525-8.
Lee et al., NF-kappaB-mediated up-regulation of Bcl-x and Bfl-1/A1 is required for CD40 survival signaling in B lymphocytes.Proc Natl Acad Sci U S A. Aug. 3, 1999;96(16):9136-41.
Mims et al., Medical Microbiology Third EditionElsevier Science, 2004, pp. 172-177.
Department of Microbiology and Immunology, 2002, USUHS, School of Medicine, pp. 113-122.
Mims et al., Medical Microbiology Third EditionElsevier Science, 2004, pp. 150-152; 429-431.
Pollack et al., Development and use of palivizumab (Synagis): a passive immunoprophylactic agent for RSV Journal of Infection and Chemotherapy, 2002 pp. 201-206.
Ettinger R et al., J Immunol. Dec. 15, 2005;175(12):7867-79.IL-21 induces differentiation of human naive and memory B cells into antibody-secreting plasma cells.
Arai et al.,Ann. Rev. Biochem., 59, 783-836 (1990).
Asao et al.,J. Immunol., 167, 1-5 (2001).
Brenne et al.,Blood, 99 (10), 3756-3762 (2002).
Genbank Accession No. AF254069.
Genbank Accession No. AF254070.
Genbank Accession No. NM—021782.
Genbank Accession No. NM—021803.
Kasaian et al.,Immunity, 16, 559-569 (2002).
Kishimoto et al.,Cell, 76, 253-262 (1994).
Leonard,Nat. Rev. Immununol., 1, 200-208 (2001).
Mehta et al.,J. Immunol., 170, 4111-4118 (2003).
Nutt et al.,Critical Reviews in Immunology, 24 (4), 239-250 (2004).
Ozaki et al.,Journal of Immunology, 173 (9), 5361-5371 (2004).
Ozaki et al.,Proc. Natl. Acad. Sci., USA, 97 (21), 11439-11444, 2000.
Ozaki et al.,Science, 298,1630-1634 (2002).
Parrish-Novak et al.,J. Leukoc. Biol., 72 (5), 856-863 (2002).
Parrish-Novak et al.,Nature, 408 (6808), 57-63 (2000).
Paul et al.,Cell, 76, 241-251, 1994.
Suto et al.,Blood, 100 (13), 4565-4573 (2002).
Calame,Nat. Immunol., 2(12), 1103-1108 (2001).
Hao et al.,J. Exp. Med, 194(8), 1151-1163 (2001).
Gause et la.,Immunology Lectures, Department of Microbiology and Immunology, USUHS, 87-91, 93-99 (2002).
Aringer et al.,J. Immunol., 170(12), 6057-6064 (2003).
Armbruster et al.J. of Antimicrobial Chemotherapy, 54, 915-920 (2004).
Arpin et al.,J. Exp. Med., 186(6), 931-940 (1997).
Baba et al,Nature Med., 6(2), 200-206 (2000).
Brandt et al.,Blood, 102(12), 4090-4098 (2003).
Breitbart et al.,J. Gerontol A. Biol. Sci. Med. Sci., 57, B304-B311 (2002).
Driver et al.,J. Immunol., 167, 1393-1405 (2001).
Ellmeier et al.,J. Exp. Med, 192(11), 1611-1623 (2000).
Ettinger et al.,J. Immunol., 176, 7867-7879 (2005).
Galun et al.,J. of Hepatology, 46, 37-44 (2007).
Genbank Accession No. NP—001189, (Sep. 8, 2003).
Jankowski, “603423: PR Domain-Containing protein 1: PRDMI,”Online Mendelian Inheritance in Man(1999).
Joos,Antimicrobial Agents and Chemotherapy, 50(5), 1773-1779 (2006).
Kerkaert,Atlas of Genetics and Cytogenetics in Oncology and Haematology, http://www.infobiogen.fr/services/chromcancer/Genes/BCL61D20.html (1998).
Kovanen et al.,lmmunol. Rev.202, 67-83 (2004).
Mascola et al.,Nature Med., 6(2), 207-210 (2000).
McHeyzer-Williams et al.,J. Exp. Med., 191(7), 1149-1165 (2000).
McKusick, “109565: B-Cell Lymphoma 6; BCL6,”Online Mendelian Inheritance in Man, (1993).
Mehta et al.,Immunol. Rv. 202, 84-95 (2004).
Mims et al.,Medical Microbiology, Third Edition, Elsevier Science, 150-152; 429-431 (2004).
Suzuki et al.,Int. Immunol., 12(2), 123-132 (2000).
SWISSPROT:BCL6—Human, Accession No. P41182 (Feb. 1, 1995).
Tangye et al.,J. Immunol., 170, 686-694 (2003).
Ukai et al.,Mol. Carcinog., 37, 110-119 (2003).
Voet,Biochemistry John Wiley and Sons, 126-128 (1990).
Vosshenrich et al.,Curr. Biol., 11(1), R175-R177 (2001).
Warnatz et al.,Blood, 99(5), 1544-1551 (2002).
Weller et al.,PNAS 98(3) 1166-1170 (2001).
Zhang et al., Abstract,Biochem. Biophys. Res. Commun., 300(2), 291-296 (2003).
Beasley et al.,Developments in Biological Standardization, 54: 363-375 (1983).
Glennie et al.,Immunology Today, 21(8): 403-410 (2000).
Hage et al.,Cell, 97: 271-281 (1999).
Hammon et al.,The Journal of the American Medical Association, 151: 1272-1285 (1953).
Havens et al.,The Journal of the American Medical Association, 129: 270-272 (1945).
Kahn et al.,The Lancet, 369: 2135-2137 (2007).
Paffenbarger et al.,The American Journal of Hygiene, 74: 311-325 (1961).
Szmuness et al.,Hepatology, 1: 377-385 (1981).
Wiley et al.,Nature, 289: 373-378 (1981).
Parham, The Immune System, 2nd Ed., Chapter 4, The development of B lymphocytes, 85-105 (2005).
Ettinger Catherine Rachel
Leonard Warren J.
Lipsky Peter
Morse, III Herbert C.
Spolski Rosanne
Leavitt Maria
Leydig & Voit & Mayer
The United States of America as represented by the Department of
LandOfFree
Method of inducing memory B cell development and terminal... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method of inducing memory B cell development and terminal..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of inducing memory B cell development and terminal... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2740711